Last reviewed · How we verify

Paclitaxel + Gemcitabine admixture

Milton S. Hershey Medical Center · Phase 3 active Small molecule

Paclitaxel + Gemcitabine admixture is a Chemotherapy combination (taxane + nucleoside analog) Small molecule drug developed by Milton S. Hershey Medical Center. It is currently in Phase 3 development for Non-small cell lung cancer, Ovarian cancer, Breast cancer.

This combination uses paclitaxel to stabilize microtubules and gemcitabine to inhibit ribonucleotide reductase, together disrupting cell division and DNA synthesis in cancer cells.

This combination uses paclitaxel to stabilize microtubules and gemcitabine to inhibit ribonucleotide reductase, together disrupting cell division and DNA synthesis in cancer cells. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.

At a glance

Generic namePaclitaxel + Gemcitabine admixture
SponsorMilton S. Hershey Medical Center
Drug classChemotherapy combination (taxane + nucleoside analog)
Targetβ-tubulin (paclitaxel); ribonucleotide reductase (gemcitabine)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Paclitaxel is a taxane that binds to β-tubulin and prevents microtubule depolymerization, halting mitosis. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and is incorporated into DNA, causing chain termination. The combination exploits complementary mechanisms to enhance cytotoxicity against rapidly dividing cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paclitaxel + Gemcitabine admixture

What is Paclitaxel + Gemcitabine admixture?

Paclitaxel + Gemcitabine admixture is a Chemotherapy combination (taxane + nucleoside analog) drug developed by Milton S. Hershey Medical Center, indicated for Non-small cell lung cancer, Ovarian cancer, Breast cancer.

How does Paclitaxel + Gemcitabine admixture work?

This combination uses paclitaxel to stabilize microtubules and gemcitabine to inhibit ribonucleotide reductase, together disrupting cell division and DNA synthesis in cancer cells.

What is Paclitaxel + Gemcitabine admixture used for?

Paclitaxel + Gemcitabine admixture is indicated for Non-small cell lung cancer, Ovarian cancer, Breast cancer, Pancreatic cancer.

Who makes Paclitaxel + Gemcitabine admixture?

Paclitaxel + Gemcitabine admixture is developed by Milton S. Hershey Medical Center (see full Milton S. Hershey Medical Center pipeline at /company/milton-s-hershey-medical-center).

What drug class is Paclitaxel + Gemcitabine admixture in?

Paclitaxel + Gemcitabine admixture belongs to the Chemotherapy combination (taxane + nucleoside analog) class. See all Chemotherapy combination (taxane + nucleoside analog) drugs at /class/chemotherapy-combination-taxane-nucleoside-analog.

What development phase is Paclitaxel + Gemcitabine admixture in?

Paclitaxel + Gemcitabine admixture is in Phase 3.

What are the side effects of Paclitaxel + Gemcitabine admixture?

Common side effects of Paclitaxel + Gemcitabine admixture include Neutropenia, Anemia, Thrombocytopenia, Peripheral neuropathy, Nausea/vomiting, Fatigue.

What does Paclitaxel + Gemcitabine admixture target?

Paclitaxel + Gemcitabine admixture targets β-tubulin (paclitaxel); ribonucleotide reductase (gemcitabine) and is a Chemotherapy combination (taxane + nucleoside analog).

Related